Bristol Myers Squibb has scored an exit from oncology therapy deveoper Ikena, whose share priced doubled on its first day of trading.
US-based cancer drug developer Ikena Oncology floated on Friday in a $125m initial public offering representing an exit for pharmaceutical firm Bristol Myers Squibb (BMS).
The offering consisted of just over 7.81 million shares priced at $16.00 each, at the middle of the IPO’s $15 to $17 range. They were issued on the Nasdaq Global Market and closed at $32.00 at the end of their first day of trading, taking its market capitalisation to nearly $483m.
Founded in 2016, Ikena…
